Baseline Preferences for Daily, Event-Driven, or Periodic HIV Pre-Exposure Prophylaxis among Gay and Bisexual Men in the PRELUDE Demonstration Project

Stefanie J Vaccher, Christopher Gianacas, David J Templeton, Isobel M Poynten, Bridget G Haire, Catriona Ooi, Rosalind Foster, Anna McNulty, Andrew E Grulich, Iryna B Zablotska, PRELUDE Study Team, Andrew Carr, Andrew Grulich, Anna McNulty, Brent Mackie, Cathy Pell, Catriona Ooi, Cheung Yvonne Ching, Chris Gianacas, David Templeton, Dean Murphy, Edwina Wright, Garrett Prestage, Isobel Mary Poynten, John de Wit, John Kaldor, John McAllister, Kenneth Mayer, Mark Bloch, Martin Holt, Nathan Ryder, Rebecca Guy, Rosalind Foster, Stefanie Vaccher, Stefanie J Vaccher, Christopher Gianacas, David J Templeton, Isobel M Poynten, Bridget G Haire, Catriona Ooi, Rosalind Foster, Anna McNulty, Andrew E Grulich, Iryna B Zablotska, PRELUDE Study Team, Andrew Carr, Andrew Grulich, Anna McNulty, Brent Mackie, Cathy Pell, Catriona Ooi, Cheung Yvonne Ching, Chris Gianacas, David Templeton, Dean Murphy, Edwina Wright, Garrett Prestage, Isobel Mary Poynten, John de Wit, John Kaldor, John McAllister, Kenneth Mayer, Mark Bloch, Martin Holt, Nathan Ryder, Rebecca Guy, Rosalind Foster, Stefanie Vaccher

Abstract

Introduction: The effectiveness of daily pre-exposure prophylaxis (PrEP) is well established. However, there has been increasing interest in non-daily dosing schedules among gay and bisexual men (GBM). This paper explores preferences for PrEP dosing schedules among GBM at baseline in the PRELUDE demonstration project.

Materials and methods: Individuals at high-risk of HIV were enrolled in a free PrEP demonstration project in New South Wales, Australia, between November 2014 and April 2016. At baseline, they completed an online survey containing detailed behavioural, demographic, and attitudinal questions, including their ideal way to take PrEP: daily (one pill taken every day), event-driven (pills taken only around specific risk events), or periodic (daily dosing during periods of increased risk).

Results: Overall, 315 GBM (98% of study sample) provided a preferred PrEP dosing schedule at baseline. One-third of GBM expressed a preference for non-daily PrEP dosing: 20% for event-driven PrEP, and 14% for periodic PrEP. Individuals with a trade/vocational qualification were more likely to prefer periodic to daily PrEP [adjusted odds ratio (aOR) = 4.58, 95% confidence intervals (95% CI): (1.68, 12.49)], compared to individuals whose highest level of education was high school. Having an HIV-positive main regular partner was associated with strong preference for daily, compared to event-driven PrEP [aOR = 0.20, 95% CI: (0.04, 0.87)]. Participants who rated themselves better at taking medications were more likely to prefer daily over periodic PrEP [aOR = 0.39, 95% CI: (0.20, 0.76)].

Discussion: Individuals' preferences for PrEP schedules are associated with demographic and behavioural factors that may impact on their ability to access health services and information about PrEP and patterns of HIV risk. At the time of data collection, there were limited data available about the efficacy of non-daily PrEP schedules, and clinicians only recommended daily PrEP to study participants. Further research investigating how behaviours and PrEP preferences change correspondingly over time is needed.

Trial registration: ClinicalTrials.gov NCT02206555. Registered 28 July 2014.

Keywords: HIV; dosing preferences; event-driven pre-exposure prophylaxis; gay and bisexual men; non-daily dosing; periodic pre-exposure prophylaxis; pre-exposure prophylaxis.

References

    1. Fonner VA, Dalglish SL, Kennedy CE, Baggaley R, O’Reilly KR, Koechlin FM, et al. Effectiveness and safety of oral HIV preexposure prophylaxis for all populations. AIDS (2016) 30(12):1973–83.10.1097/QAD.0000000000001145
    1. Brooks RA, Landovitz RJ, Kaplan RL, Lieber E, Lee SJ, Barkley TW. Sexual risk behaviors and acceptability of HIV pre-exposure prophylaxis among HIV-negative gay and bisexual men in serodiscordant relationships: a mixed methods study. AIDS Patient Care STDS (2012) 26(2):87–94.10.1089/apc.2011.0283
    1. Grant RM, Anderson PL, McMahan V, Liu A, Amico KR, Mehrotra M, et al. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis (2014) 14(9):820–9.10.1016/S1473-3099(14)70847-3
    1. Young I, Flowers P, McDaid LM. Barriers to uptake and use of pre-exposure prophylaxis (PrEP) among communities most affected by HIV in the UK: findings from a qualitative study in Scotland. BMJ Open (2014) 4(11):e005717.10.1136/bmjopen-2014-005717
    1. Grov C, Whitfield TH, Rendina HJ, Ventuneac A, Parsons JT. Willingness to take PrEP and potential for risk compensation among highly sexually active gay and bisexual men. AIDS Behav (2015) 19(12):2234–44.10.1007/s10461-015-1030-1
    1. Mera Giler R, Trevor H, Bush S, Rawlings K, McCallister S. Changes in truvada (TVD) for HIV pre-exposure prophylaxis (PrEP) utilization in the United States: (2012-2016). IAS 2017; Paris, France: (2017).
    1. Grulich A. Taking PrEP to scale for gay and bisexual men in Australia. IAS 2017; Paris, France: (2017).
    1. Van der Elst EM, Mbogua J, Operario D, Mutua G, Kuo C, Mugo P, et al. High acceptability of HIV pre-exposure prophylaxis but challenges in adherence and use: qualitative insights from a phase I trial of intermittent and daily PrEP in at-risk populations in Kenya. AIDS Behav (2013) 17(6):2162–72.10.1007/s10461-012-0317-8
    1. Castro JG, Jones DL, Weiss SM. STD patients’ preferences for HIV prevention strategies. HIV AIDS (Auckl) (2014) 6:171–5.10.2147/HIV.S71975
    1. Elsesser SA, Oldenburg CE, Biello KB, Mimiaga MJ, Safren SA, Egan JE, et al. Seasons of risk: anticipated behavior on vacation and interest in episodic antiretroviral pre-exposure prophylaxis (PrEP) among a large national sample of U.S. Men who have sex with men (MSM). AIDS Behav (2016) 20(7):1400–7.10.1007/s10461-015-1238-0
    1. Stack C, Oldenburg C, Mimiaga M, Elsesser SA, Krakower D, Novak DS, et al. Sexual behavior patterns and PrEP dosing preferences in a large sample of North American men who have sex with men. J Acquir Immune Defic Syndr (2016) 71(1):94–101.10.1097/QAI.0000000000000816
    1. Roberts ST, Heffron R, Ngure K, Celum C, Kurth A, Curran K, et al. Preferences for daily or intermittent pre-exposure prophylaxis regimens and ability to anticipate sex among HIV uninfected members of Kenyan HIV serodiscordant couples. AIDS Behav (2014) 18(9):1701–11.10.1007/s10461-014-0804-1
    1. Ferrer L, Folch C, Fernandez-Davila P, Garcia A, Morales A, Belda J, et al. Awareness of pre-exposure prophylaxis for HIV, willingness to use it and potential barriers or facilitators to uptake among men who have sex with men in Spain. AIDS Behav (2016) 20(7):1423–33.10.1007/s10461-016-1379-9
    1. Spinner CD, Boesecke C, Zink A, Jessen H, Stellbrink HJ, Rockstroh JK, et al. HIV pre-exposure prophylaxis (PrEP): a review of current knowledge of oral systemic HIV PrEP in humans. Infection (2015) 44(2):151–8.10.1007/s15010-015-0850-2
    1. Mannheimer S, Hirsch-Moverman Y, Loquere A, Franks J, Hughes J, Ou S, et al. HPTN 067/ADAPT study: a comparison of daily and intermittent pre-exposure prophylaxis (PrEP) dosing for HIV prevention in men who have sex with men and transgender women in New York city. IAS 2015; Vancouver, Canada: (2015).
    1. Kibengo FM, Ruzagira E, Katende D, Bwanika AN, Bahemuka U, Haberer JE, et al. Safety, adherence and acceptability of intermittent tenofovir/emtricitabine as HIV pre-exposure prophylaxis (PrEP) among HIV-uninfected Ugandan volunteers living in HIV-serodiscordant relationships: a randomized, clinical trial. PLoS One (2013) 8(9):e74314.10.1371/journal.pone.0074314
    1. Amico KR, Wallace M, Bekker LG, Roux S, Atujuna M, Sebastian E, et al. Experiences with HPTN 067/ADAPT study-provided open-label PrEP among women in Cape Town: facilitators and barriers within a mutuality framework. AIDS Behav (2017) 21(5):1361–75.10.1007/s10461-016-1458-y
    1. Grant RM, Liegler T, Defechereux P, Kashuba AD, Taylor D, Abdel-Mohsen M, et al. Drug resistance and plasma viral RNA level after ineffective use of oral pre-exposure prophylaxis in women. AIDS (2015) 29(3):331–7.10.1097/QAD.0000000000000556
    1. Patterson KB, Prince HA, Kraft E, Jenkins AJ, Shaheen NJ, Rooney JF, et al. Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission. Sci Transl Med (2011) 3(112):112re4.10.1126/scitranslmed.3003174
    1. Anderson PL, Glidden DV, Liu A, Buchbinder S, Lama JR, Guanira JV, et al. Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med (2012) 4(151):151ra125.10.1126/scitranslmed.3004006
    1. EACS. European AIDS Clinical Society Guidelines Version 8.0. London: European AIDS Clinical Society (EACS) (2015).
    1. WHO. Consolidated Guidelines on HIV Prevention, Diagnosis, Treatment and Care for Key Populations – 2016 Update. France: World Health Organisation; (2016).
    1. Wright E, Grulich A, Roy K, Boyd M, Cornelisse V, Russell D, et al. Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine HIV pre-exposure prophylaxis: clinical guidelines. J Virus Erad (2017) 3(3):168–84.
    1. Vaccher S, Grulich A, McAllister J, Templeton DJ, Bloch M, McNulty A, et al. Protocol for an open-label, single-arm trial of HIV pre-exposure prophylaxis (PrEP) among people at high risk of HIV infection: the NSW Demonstration Project PRELUDE. BMJ Open (2016) 6(6):e012179.10.1136/bmjopen-2016-012179
    1. Hosmer D, Lemeshow S, Sturdivant RX. Applied Logisitic Regression. Hoboken, NJ: John Wiley & Sons, Inc; (2013). 528 p.10.1002/9781118548387
    1. Perez-Figueroa RE, Kapadia F, Barton SC, Eddy JA, Halkitis PN. Acceptability of PrEP uptake among racially/ethnically diverse young men who have sex with men: the P18 study. AIDS Educ Prev (2015) 27(2):112–25.10.1521/aeap.2015.27.2.112
    1. Doblecki-Lewis S, Liu A, Feaster D, Cohen SE, Cardenas G, Bacon O, et al. Healthcare access and PrEP continuation in San Francisco and Miami after the US PrEP demo project. J Acquir Immune Defic Syndr (2017) 74(5):531–8.10.1097/QAI.0000000000001236
    1. Mayer KH, Oldenburg CE, Novak DS, Elsesser SA, Krakower DS, Mimiaga MJ. Early adopters: correlates of HIV chemoprophylaxis use in recent online samples of US men who have sex with men. AIDS Behav (2016) 20(7):1489–98.10.1007/s10461-015-1237-1
    1. van der Heide I, Wang J, Droomers M, Spreeuwenberg P, Rademakers J, Uiters E. The relationship between health, education, and health literacy: results from the Dutch Adult Literacy and Life Skills Survey. J Health Commun (2013) 18(Suppl 1):172–84.10.1080/10810730.2013.825668
    1. Rudd RE. Health literacy skills of U.S. adults. Am J Health Behav (2007) 31(Suppl 1):S8–18.10.5993/AJHB.31.s1.3
    1. Kutner M, Greenberg E, Jin Y, Paulsen C, White S. The Health Literacy of America’s Adults: Results From the 2003 National Assessment of Adult Literacy. Washington, DC: US Department of Education; (2006).
    1. Closson EF, Mitty JA, Malone J, Mayer KH, Mimiaga MJ. Exploring strategies for PrEP adherence and dosing preferences in the context of sexualized recreational drug use among MSM: a qualitative study. AIDS Care (2017):1–8.10.1080/09540121.2017.1360992
    1. Vernazza P, Hirschel B, Bernasconi E, Flepp M. Les personnes séropositives ne souffrant d’aucune autre MST et suivant un traitement antirétroviral efficace ne transmettent pas le VIH par voie sexuelle. Bull Med Suisse (2008) 89(5):165–9.
    1. Bavinton B, Grinsztejn B, Phanuphak N, Jin F, Zablotska I, Prestage G, et al. The Opposites Attract Study Group HIV treatment prevents HIV transmission in male serodiscordant couples in Australia, Thailand and Brazil. IAS 2017; Paris, France: (2017).
    1. Bavinton BR, Grulich AE, Duncan D, Zablotska IB, Prestage GP. How partnership type and HIV seroconcordance affect HIV transmission risk in regular sexual partnerships: a cross-sectional survey of Australian gay and bisexual men. Sex Health (2017) 14(6):523–32.10.1071/SH16198
    1. Prestage G, Duncan D, Grierson J, Bradley J, Bavinton B, Kolstee J, et al. Monopoly: A Study of Gay Men’s Relationships. Sydney: The Kirby Institute, UNSW Sydney; (2014).
    1. Hoenigl M, Chaillon A, Moore DJ, Morris SR, Smith DM, Little SJ. Clear links between starting methamphetamine and increasing sexual risk behavior: a cohort study among men who have sex with men. J Acquir Immune Defic Syndr (2016) 71(5):551–7.10.1097/QAI.0000000000000888
    1. Martin M, Vanichseni S, Suntharasamai P, Sangkum U, Mock PA, Leethochawalit M, et al. The impact of adherence to preexposure prophylaxis on the risk of HIV infection among people who inject drugs. AIDS (2015) 29(7):819–24.10.1097/QAD.0000000000000613
    1. Brewis J, Linstead S. Time after time. Time Soc (1998) 7(2–3):223–48.10.1177/0961463X98007002004
    1. AVAC. PrEP Watch – France. (2017). Available from:
    1. WHO. WHO Implementation Tool for Pre-Exposure Prophylaxis (PrEP) of HIV Infection. Module 1: Clinical. Geneva: World Health Organisation; (2017).
    1. Parsons JT, Rendina HJ, Lassiter JM, Whitfield TH, Starks TJ, Grov C. Uptake of HIV pre-exposure prophylaxis (PrEP) in a national cohort of gay and bisexual men in the United States. J Acquir Immune Defic Syndr (2017) 74(3):285–92.10.1097/QAI.0000000000001251
    1. Molina JMC, Spire B, Pialoux G, Chidiac C, Charreau I, Tremblay C, et al. On demand PrEP with oral TDF-FTC in MSM: results of the ANRS Ipergay trial. CROI; Seattle, Washington: (2015).
    1. Brooks RA, Kaplan RL, Lieber E, Landovitz RJ, Lee SJ, Leibowitz AA. Motivators, concerns, and barriers to adoption of preexposure prophylaxis for HIV prevention among gay and bisexual men in HIV-serodiscordant male relationships. AIDS Care (2011) 23(9):1136–45.10.1080/09540121.2011.554528
    1. Galea JT, Kinsler JJ, Salazar X, Lee SJ, Giron M, Sayles JN, et al. Acceptability of pre-exposure prophylaxis as an HIV prevention strategy: barriers and facilitators to pre-exposure prophylaxis uptake among at-risk Peruvian populations. Int J STD AIDS (2011) 22(5):256–62.10.1258/ijsa.2009.009255
    1. Volk JE, Marcus JL, Phengrasamy T, Blechinger D, Nguyen DP, Follansbee S, et al. No new HIV infections with increasing use of HIV preexposure prophylaxis in a clinical practice setting. Clin Infect Dis (2015) 61(10):1601–3.10.1093/cid/civ778

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever